MCID: EST001
MIFTS: 48

Estrogen-Receptor Positive Breast Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

Aliases & Descriptions for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to breast cancer and mouth disease. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Letrozole and Toremifene have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are Decreased viability and cellular

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 breast cancer 11.1
2 mouth disease 10.3 ERBB2 PGR
3 bartholin's gland benign neoplasm 10.3 ESR1 PGR
4 aortitis 10.3 PGR TP53
5 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
6 bladder clear cell adenocarcinoma 10.3 ESR1 TP53
7 appendix leiomyoma 10.3 ESR1 PGR
8 bronchus adenoma 10.3 ESR1 PGR
9 skeletal tuberculosis 10.3 CCND1 ERBB2
10 ovarian benign neoplasm 10.3 ESR1 PGR
11 plexiform neurofibroma 10.3 ESR1 PGR
12 anal neuroendocrine tumor 10.3 CCND1 ESR1 PGR
13 glioma 10.3 ERBB2 ESR1 PGR
14 vaginal adenosarcoma 10.3 ESR1 PGR TP53
15 paraphimosis 10.3 ESR1 PGR TP53
16 cervical lymphoepithelioma-like carcinoma 10.3 ERBB2 ESR1 PGR
17 histiocytic and dendritic cell cancer 10.3 ERBB2 ESR1 PGR
18 nervous system hibernoma 10.3 ERBB2 ESR1 PGR
19 adult central nervous system mature teratoma 10.3 CCND1 ERBB2 TP53
20 paranasal sinus disease 10.3 ESR1 PGR
21 poliomyelitis 10.3 ERBB2 ESR1 PGR
22 oro-mandibular-limb hypogenesis syndrome 10.3 CCND1 ERBB2 TP53
23 rectal neoplasm 10.3 ERBB2 ESR1 PGR
24 combined t cell and b cell immunodeficiency 10.3 ERBB2 ESR1 PGR
25 polyembryoma of the ovary 10.3 ERBB2 ESR1 PGR
26 pericardium leiomyoma 10.2 PGR TP53
27 anus adenocarcinoma 10.2 ERBB2 ESR1 PGR
28 sclerosing hemangioma 10.2 ERBB2 ESR1 PGR
29 t-cell adult acute lymphocytic leukemia 10.2 ERBB2 ESR1 PGR
30 retinal disease 10.2 ERBB2 ESR1 PGR
31 organ system benign neoplasm 10.2 ERBB2 ESR1 PGR
32 intestinal neuroendocrine benign tumor 10.2 ERBB2 PGR PIK3CA
33 infiltrating angiolipoma 10.2 ERBB2 PGR PIK3CA
34 immunodeficiency due to a late component of complement deficiency 10.2 ERBB2 PGR TP53
35 fallopian tube adenocarcinoma 10.2 ERBB2 ESR1 TP53
36 plague 10.2 ERBB2 ESR1 TP53
37 osteogenesis imperfecta 10.2 CYP19A1 ESR1 PGR
38 folliculitis 10.2 MTOR PIK3CA
39 hemorrhagic proctocolitis 10.2 CCND1 MTOR PIK3CA
40 acute thyroiditis 10.2 CYP19A1 ESR1 PGR
41 perinatal jaundice due to hepatocellular damage 10.2 CYP19A1 ESR1 PGR
42 deafness, autosomal recessive 74 10.2 CYP19A1 ESR1 PGR
43 villoglandular endometrial endometrioid adenocarcinoma 10.2 CCND1 ESR1 PGR TP53
44 gangliosidosis gm1 10.2 ESR1 MTOR PGR
45 hypogonadotropic hypogonadism 14 with or without anosmia 10.2 ERBB2 FGFR2
46 esophagus sarcoma 10.2 CYP19A1 ESR1 PGR
47 megalencephaly-capillary malformation-polymicrogyria syndrome, somatic 10.2 MTOR PIK3CA TP53
48 mediastinum synovial sarcoma 10.2 MTOR PIK3CA TP53
49 mucoepidermoid thyroid carcinoma 10.2 ERBB2 PGR
50 central nervous system mature teratoma 10.2 ERBB2 ESR1 PGR TP53

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.28 MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.28 HSPB8
3 Decreased viability GR00221-A-1 10.28 ESR1 HSPB8 MTOR PIK3CA AKT1
4 Decreased viability GR00221-A-2 10.28 ESR1 PIK3CA AKT1
5 Decreased viability GR00221-A-3 10.28 ERBB2 AKT1
6 Decreased viability GR00221-A-4 10.28 ERBB2 ESR1 HSPB8 MTOR PIK3CA AKT1
7 Decreased viability GR00301-A 10.28 HSPB8
8 Decreased viability GR00342-S-1 10.28 MTOR
9 Decreased viability GR00342-S-2 10.28 MTOR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.21 MTOR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.21 MTOR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.21 FOXA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.21 CCND1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.21 FOXA1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.21 NCOA3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.21 FOXA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.21 NCOA3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.21 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.21 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 CCND1 FOXA1 MTOR AKT1 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.21 PIK3CA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.21 FOXA1 AKT1 PIK3CA CCND1 NCOA3
24 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.21 FOXA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 PIK3CA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.21 FOXA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 CCND1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.21 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 FOXA1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.21 FOXA1 MTOR AKT1 PIK3CA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.21 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.21 AKT1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 FOXA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.21 AKT1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.21 MTOR
39 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.21 AKT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.21 NCOA3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.21 MTOR AKT1

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
2 homeostasis/metabolism MP:0005376 10.39 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
3 behavior/neurological MP:0005386 10.37 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
4 endocrine/exocrine gland MP:0005379 10.36 ESR1 FGFR2 FOXA1 MTOR NCOA3 PGR
5 cardiovascular system MP:0005385 10.32 ERBB2 ESR1 FGFR2 HSPB8 MTOR PGR
6 growth/size/body region MP:0005378 10.31 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
7 immune system MP:0005387 10.31 AKT1 CCND1 CYP19A1 ESR1 FGFR2 FOXA1
8 mortality/aging MP:0010768 10.28 AKT1 CCND1 ERBB2 ESR1 FGFR2 FOXA1
9 integument MP:0010771 10.26 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
10 adipose tissue MP:0005375 10.25 AKT1 CYP19A1 ESR1 FGFR2 MTOR NCOA3
11 hematopoietic system MP:0005397 10.22 PGR STAT5B TP53 AKT1 CCND1 CYP19A1
12 embryo MP:0005380 10.21 AKT1 ERBB2 TP53 ESR1 FGFR2 MTOR
13 digestive/alimentary MP:0005381 10.17 TP53 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
14 muscle MP:0005369 10.14 AKT1 CYP19A1 ERBB2 ESR1 FGFR2 HSPB8
15 neoplasm MP:0002006 10.07 PGR PIK3CA TP53 AKT1 CCND1 ERBB2
16 normal MP:0002873 10.06 MTOR NCOA3 PGR STAT5B TP53 AKT1
17 liver/biliary system MP:0005370 10 AKT1 CYP19A1 ESR1 FGFR2 NCOA3 STAT5B
18 reproductive system MP:0005389 9.9 AKT1 CCND1 CYP19A1 ERBB2 ESR1 TP53
19 renal/urinary system MP:0005367 9.8 CYP19A1 ESR1 FGFR2 MTOR NCOA3 STAT5B
20 respiratory system MP:0005388 9.56 AKT1 CCND1 ERBB2 ESR1 FGFR2 HSPB8
21 skeleton MP:0005390 9.36 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 303)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
2
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
7
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
8
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
9
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
10
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
11
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
12
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
13
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124 9877265
14 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
27 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
33 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1 180288-69-1 9903
36
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
37
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
38
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
39
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
40
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
41
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
42
Thiotepa Approved Phase 3,Phase 2 52-24-4 5453
43
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
44
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
45
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
46
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
47
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
48
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
49
Tibolone Approved Phase 3 5630-53-5
50
Aminoglutethimide Approved Phase 3 125-84-8 2145

Interventional clinical trials:

(show top 50) (show all 517)
id Name Status NCT ID Phase
1 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
2 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4
3 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4
4 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Recruiting NCT01231659 Phase 4
5 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4
6 Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer Recruiting NCT02549677 Phase 4
7 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Recruiting NCT01176916 Phase 4
8 Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients Recruiting NCT02062489 Phase 4
9 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Not yet recruiting NCT03137368 Phase 4
10 Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Terminated NCT01239745 Phase 4
11 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3
12 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Unknown status NCT00541086 Phase 3
13 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3
14 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3
15 Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women Unknown status NCT00912548 Phase 3
16 Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer Unknown status NCT00629278 Phase 3
17 Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer Unknown status NCT01622361 Phase 3
18 Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer Unknown status NCT00003680 Phase 3
19 Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00010140 Phase 3
20 Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes Completed NCT00966043 Phase 3
21 Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Completed NCT00050011 Phase 3
22 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Completed NCT01626222 Phase 3
23 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed NCT00863655 Phase 3
24 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3
25 Faslodex Advanced Breast Cancer Local Chinese Study Completed NCT00327769 Phase 3
26 Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer Completed NCT00002967 Phase 3
27 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3
28 Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer Completed NCT00002646 Phase 3
29 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
30 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3
31 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3
32 Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women Completed NCT01300351 Phase 3
33 Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer Completed NCT00002720 Phase 3
34 A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469) Completed NCT00725374 Phase 3
35 Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer Completed NCT01986569 Phase 3
36 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer Completed NCT00293540 Phase 3
37 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Completed NCT00201851 Phase 3
38 Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer Completed NCT00002529 Phase 3
39 ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation. Completed NCT00291759 Phase 3
40 Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes Completed NCT00004125 Phase 3
41 Tamoxifen in Treating Women With High-Risk Breast Cancer Completed NCT00002542 Phase 3
42 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3
43 Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients Completed NCT00309491 Phase 3
44 Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients Completed NCT00309478 Phase 3
45 Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy Completed NCT00256698 Phase 3
46 Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) Completed NCT00590785 Phase 3
47 ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years Completed NCT00286117 Phase 3
48 The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer Completed NCT00065325 Phase 3
49 SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer Completed NCT00929591 Phase 3
50 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed NCT00171704 Phase 3

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

39
Breast, Lymph Node, Bone, Testes, Endothelial, Neutrophil, B Cells

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 339)
id Title Authors Year
1
Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. ( 27866092 )
2017
2
Glycone-rich Soy Isoflavone Extracts Promote Estrogen Receptor Positive Breast Cancer Cell Growth. ( 27043076 )
2016
3
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. ( 27217450 )
2016
4
MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-I^ signaling in estrogen receptor positive breast cancer cells. ( 27014911 )
2016
5
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. ( 26987533 )
2016
6
CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. ( 26812885 )
2016
7
Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha. ( 27491559 )
2016
8
A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. ( 26606746 )
2016
9
Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-Negative and Estrogen Receptor Positive Breast Cancer Cells: An Integrated Experimental and Computational Study. ( 27129269 )
2016
10
Correction: Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. ( 27698190 )
2016
11
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. ( 26976426 )
2016
12
CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer. ( 27301701 )
2016
13
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer. ( 27373750 )
2016
14
Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer. ( 27332719 )
2016
15
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. ( 27640304 )
2016
16
Cost-effectiveness assessment of lumpectomy cavity boost in elderly women with early stage estrogen receptor positive breast cancer receiving adjuvant radiotherapy. ( 26867968 )
2016
17
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. ( 27894097 )
2016
18
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. ( 26857361 )
2016
19
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. ( 27367583 )
2016
20
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. ( 27999738 )
2016
21
Impact of Cooperative Trial and Sociodemographic Variation on Adjuvant Radiation Therapy Usage in Elderly Women (a8Y70 Years) with Stage I, Estrogen Receptor-Positive Breast Cancer: Analysis of the National Cancer Data Base. ( 26831366 )
2016
22
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. ( 27246191 )
2016
23
Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer. ( 27986439 )
2016
24
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. ( 27020857 )
2016
25
Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. ( 27926932 )
2016
26
Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. ( 26958999 )
2016
27
Characterization of the interactions between calmodulin and death receptor 5 in triple-negative and estrogen receptor-positive breast cancer cells. AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. ( 27815452 )
2016
28
The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer. ( 27314197 )
2016
29
Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer. ( 27001589 )
2016
30
Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further Evolution. ( 26633601 )
2016
31
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. ( 27722840 )
2016
32
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. ( 27388210 )
2016
33
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. ( 27016037 )
2016
34
KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients. ( 27835900 )
2016
35
Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort. ( 28003027 )
2016
36
Upregulation of HSF1 in estrogen receptor positive breast cancer. ( 27713164 )
2016
37
BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency. ( 27620280 )
2016
38
Inhibition of ERI+/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine. ( 27384485 )
2016
39
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. ( 27102299 )
2016
40
Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. ( 26257067 )
2015
41
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. ( 26096934 )
2015
42
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells. ( 25837259 )
2015
43
ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer. ( 26722530 )
2015
44
FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients. ( 25707489 )
2015
45
Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptor-positive Breast Cancer. ( 26408687 )
2015
46
Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. ( 25878567 )
2015
47
Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients. ( 25640367 )
2015
48
Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer. ( 25771071 )
2015
49
17I^-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells. ( 26022099 )
2015
50
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. ( 26031545 )
2015

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 AKT1 CCND1 ERBB2 FGFR2 MTOR STAT5B
2
Show member pathways
13.4 AKT1 CCND1 ERBB2 FGFR2 PIK3CA STAT5B
3
Show member pathways
13.17 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
4
Show member pathways
12.94 AKT1 CCND1 PIK3CA STAT5B TP53
5
Show member pathways
12.9 AKT1 ERBB2 FGFR2 MTOR PIK3CA
6
Show member pathways
12.86 AKT1 CCND1 ESR1 MTOR PIK3CA STAT5B
7
Show member pathways
12.85 AKT1 CCND1 PIK3CA STAT5B TP53
8
Show member pathways
12.85 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
9
Show member pathways
12.84 AKT1 CCND1 MTOR PIK3CA STAT5B
10
Show member pathways
12.78 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
11
Show member pathways
12.65 AKT1 ERBB2 PIK3CA STAT5B TP53
12 12.63 AKT1 CCND1 FGFR2 MTOR PIK3CA TP53
13 12.6 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
14 12.59 CCND1 ERBB2 MTOR PIK3CA TP53
15
Show member pathways
12.59 AKT1 CCND1 ERBB2 MTOR PIK3CA TP53
16
Show member pathways
12.52 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
17
Show member pathways
12.5 AKT1 CCND1 MTOR PIK3CA TP53
18 12.48 AKT1 CCND1 PIK3CA STAT5B TP53
19
Show member pathways
12.47 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
20
Show member pathways
12.46 AKT1 FGFR2 MTOR PIK3CA
21
Show member pathways
12.46 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
22
Show member pathways
12.4 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
23 12.35 CCND1 PIK3CA STAT5B TP53
24
Show member pathways
12.33 AKT1 CCND1 ERBB2 MTOR PIK3CA STAT5B
25
Show member pathways
12.31 AKT1 MTOR STAT5B TP53
26
Show member pathways
12.31 AKT1 CCND1 ERBB2 ESR1 NCOA3 PIK3CA
27
Show member pathways
12.28 CCND1 ESR1 NCOA3 PGR
28
Show member pathways
12.26 AKT1 CCND1 MTOR PIK3CA STAT5B
29
Show member pathways
12.24 AKT1 MTOR PIK3CA TP53
30
Show member pathways
12.23 AKT1 FGFR2 MTOR PIK3CA
31
Show member pathways
12.23 AKT1 CCND1 ERBB2 MTOR PIK3CA STAT5B
32 12.22 AKT1 ERBB2 MTOR NCOA3 STAT5B
33
Show member pathways
12.22 AKT1 CCND1 ERBB2 ESR1 FGFR2 MTOR
34
Show member pathways
12.2 AKT1 MTOR PIK3CA TP53
35
Show member pathways
12.19 AKT1 CCND1 ERBB2 FGFR2 MTOR TP53
36 12.17 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
37 12.15 AKT1 CCND1 MTOR TP53
38
Show member pathways
12.15 AKT1 CCND1 ERBB2 MTOR PIK3CA
39 12.14 AKT1 CCND1 MTOR PIK3CA TP53
40
Show member pathways
12.1 AKT1 ERBB2 PIK3CA TP53
41
Show member pathways
12.08 AKT1 CCND1 ERBB2 PIK3CA STAT5B TP53
42 12.04 AKT1 CCND1 MTOR TP53
43
Show member pathways
12.01 AKT1 MTOR TP53
44 12.01 AKT1 CCND1 ERBB2 PIK3CA TP53
45 11.99 AKT1 CCND1 CYP19A1 ESR1 MTOR NCOA3
46 11.97 AKT1 CCND1 PIK3CA STAT5B
47 11.97 AKT1 ERBB2 MTOR PIK3CA
48
Show member pathways
11.96 ERBB2 ESR1 PGR PIK3CA STAT5B
49 11.95 AKT1 MTOR PIK3CA
50 11.94 AKT1 ESR1 MTOR

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 AKT1 CCND1 ERBB2 ESR1 FGFR2 FOXA1
2 nucleoplasm GO:0005654 9.4 AKT1 CCND1 ESR1 FGFR2 FOXA1 HSPB8
3 phosphatidylinositol 3-kinase complex GO:0005942 9.16 MTOR PIK3CA

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.95 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.86 AKT1 ESR1 FGFR2 FOXA1 NCOA3 PGR
3 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.83 AKT1 ESR1 FOXA1
4 cellular response to hypoxia GO:0071456 9.83 AKT1 MTOR TP53
5 protein autophosphorylation GO:0046777 9.83 AKT1 ERBB2 FGFR2 MTOR
6 phosphatidylinositol phosphorylation GO:0046854 9.82 ERBB2 FGFR2 PIK3CA
7 positive regulation of protein phosphorylation GO:0001934 9.81 AKT1 CCND1 ERBB2 MTOR
8 wound healing GO:0042060 9.8 ERBB2 FGFR2 MTOR
9 T cell costimulation GO:0031295 9.77 AKT1 MTOR PIK3CA
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 AKT1 FGFR2 MTOR
11 cellular response to growth factor stimulus GO:0071363 9.72 AKT1 ERBB2 STAT5B
12 cellular response to epidermal growth factor stimulus GO:0071364 9.67 AKT1 ERBB2 STAT5B
13 response to estradiol GO:0032355 9.67 CCND1 ESR1 FOXA1 STAT5B
14 TOR signaling GO:0031929 9.65 AKT1 MTOR
15 regulation of myelination GO:0031641 9.63 AKT1 MTOR
16 positive regulation of lipid biosynthetic process GO:0046889 9.62 AKT1 MTOR
17 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.62 ERBB2 MTOR
18 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.62 AKT1 ERBB2 FGFR2 PIK3CA
19 negative regulation of cell size GO:0045792 9.61 AKT1 MTOR
20 mitotic G1 DNA damage checkpoint GO:0031571 9.6 CCND1 TP53
21 regulation of glycogen biosynthetic process GO:0005979 9.58 AKT1 MTOR
22 regulation of multicellular organism growth GO:0040014 9.58 FGFR2 PIK3CA STAT5B
23 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.57 ESR1 FGFR2
24 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.54 ESR1 FGFR2
25 response to UV-A GO:0070141 9.46 AKT1 CCND1
26 prostate epithelial cord elongation GO:0060523 9.43 ESR1 FGFR2
27 negative regulation of macroautophagy GO:0016242 9.33 AKT1 MTOR PIK3CA
28 anoikis GO:0043276 9.13 AKT1 MTOR PIK3CA
29 phosphatidylinositol-mediated signaling GO:0048015 9.1 AKT1 ERBB2 FGFR2 MTOR PIK3CA TP53
30 regulation of transcription, DNA-templated GO:0006355 10.26 CCND1 ERBB2 ESR1 FOXA1 NCOA3 PGR
31 transcription, DNA-templated GO:0006351 10.23 CCND1 ERBB2 ESR1 FOXA1 NCOA3 PGR
32 positive regulation of transcription, DNA-templated GO:0045893 10.04 AKT1 ESR1 NCOA3 TOX3 TP53

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.76 ESR1 FOXA1 PGR STAT5B
2 kinase activity GO:0016301 9.73 AKT1 CCND1 ERBB2 FGFR2 MTOR PIK3CA
3 protein kinase binding GO:0019901 9.72 AKT1 CCND1 ESR1 MTOR TP53
4 protein phosphatase binding GO:0019903 9.61 ERBB2 STAT5B TP53
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 ERBB2 FGFR2 PIK3CA
6 enzyme binding GO:0019899 9.55 AKT1 CCND1 ESR1 PGR TP53
7 nitric-oxide synthase regulator activity GO:0030235 9.37 AKT1 ESR1
8 protein kinase activity GO:0004672 9.1 AKT1 CCND1 ERBB2 FGFR2 HSPB8 MTOR
9 estrogen response element binding GO:0034056 8.96 ESR1 TOX3

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....